Metarrestin is primarily investigated for its potential in cancer therapy, specifically as an inhibitor of metastasis—the spread of cancer cells to distant organs. It targets perinucleolar compartments, which are associated with aggressive cancer phenotypes, particularly in pancreatic, prostate, and breast cancers. By disrupting these structures, metarrestin interferes with the transcriptional machinery that supports tumor cell survival and migration. The compound has shown efficacy in preclinical models by reducing tumor invasion and metastatic burden without significant toxicity. It appears to modulate key signaling pathways involved in epithelial-mesenchymal transition (EMT), a critical process in cancer progression. Due to its unique mechanism of action, metarrestin is being explored as a potential therapeutic for advanced-stage cancers where metastasis is a major challenge. Its development represents a novel strategy in oncology—targeting the structural organization of the nucleus to impair cancer aggressiveness.